Leticia González-Blanco1, María P García-Portilla2, Leticia García-Álvarez3, Lorena de la Fuente-Tomás3, Celso Iglesias García4, Pilar A Sáiz1, Susana Rodríguez-González5, Ana Coto-Montes5, Julio Bobes1. 1. Área de Psiquiatría, Universidad de Oviedo, Oviedo, España; Servicio de Salud del Principado de Asturias, Oviedo, España; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Oviedo, España; Instituto de Neurociencias del Principado de Asturias (INEUROPA), Oviedo, España. 2. Área de Psiquiatría, Universidad de Oviedo, Oviedo, España; Servicio de Salud del Principado de Asturias, Oviedo, España; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Oviedo, España; Instituto de Neurociencias del Principado de Asturias (INEUROPA), Oviedo, España. Electronic address: albert@uniovi.es. 3. Área de Psiquiatría, Universidad de Oviedo, Oviedo, España; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Oviedo, España; Instituto de Neurociencias del Principado de Asturias (INEUROPA), Oviedo, España. 4. Área de Psiquiatría, Universidad de Oviedo, Oviedo, España; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Oviedo, España; Instituto de Neurociencias del Principado de Asturias (INEUROPA), Oviedo, España; Servicio de Salud del Principado de Asturias, Langreo, España. 5. Departamento de Morfología y Biología Celular, Universidad de Oviedo, Oviedo, España.
Abstract
INTRODUCTION: Evidence suggests the existence of cytokine disturbances in patients with schizophrenia but their association with psychopathology is still unclear. The aim of the current study was to determine if pro-inflammatory cytokine levels (tumor necrosis factor-α, interleukin (IL)-6, IL-2, IL-1β, IL-1RA) are increased in stable outpatients compared with healthy subjects, and to analyze if they could be specific biomarkers of clinical dimensions in schizophrenia. METHODS: We studied 73 stable outpatients with schizophrenia in their first 10 years of illness and 73 age- and sex-matched healthy controls. An accurate assessment of clinical dimensions (positive, negative, depressive, cognitive) was performed in patients. RESULTS: Only IL-6 levels were significantly increased in patients after controlling for body mass index, waist circumference, smoking, and psychopharmacological treatment, compared with healthy subjects. After adjusting for several confounders, multiple linear regression models identified that Positive and Negative Syndrome Scale negative symptoms, general psychopathology, and global severity are predicted by IL-1β concentrations, while motivation and pleasure domain of Clinical Assessment Interview for Negative Symptoms and Personal and Social Performance global functioning scores are predicted by IL-2 levels. Cognitive performance, positive, and depressive symptom severity did not correlate with any cytokine. CONCLUSIONS: Our findings suggested that IL-6 concentrations are elevated in stable patients with schizophrenia. Whereas IL-2 specifically marks severity of the motivation and pleasure domain of negative symptoms, IL-1β is not specific to this dimension as it also predicts severity of general and global symptomatology.
INTRODUCTION: Evidence suggests the existence of cytokine disturbances in patients with schizophrenia but their association with psychopathology is still unclear. The aim of the current study was to determine if pro-inflammatory cytokine levels (tumor necrosis factor-α, interleukin (IL)-6, IL-2, IL-1β, IL-1RA) are increased in stable outpatients compared with healthy subjects, and to analyze if they could be specific biomarkers of clinical dimensions in schizophrenia. METHODS: We studied 73 stable outpatients with schizophrenia in their first 10 years of illness and 73 age- and sex-matched healthy controls. An accurate assessment of clinical dimensions (positive, negative, depressive, cognitive) was performed in patients. RESULTS: Only IL-6 levels were significantly increased in patients after controlling for body mass index, waist circumference, smoking, and psychopharmacological treatment, compared with healthy subjects. After adjusting for several confounders, multiple linear regression models identified that Positive and Negative Syndrome Scale negative symptoms, general psychopathology, and global severity are predicted by IL-1β concentrations, while motivation and pleasure domain of Clinical Assessment Interview for Negative Symptoms and Personal and Social Performance global functioning scores are predicted by IL-2 levels. Cognitive performance, positive, and depressive symptom severity did not correlate with any cytokine. CONCLUSIONS: Our findings suggested that IL-6 concentrations are elevated in stable patients with schizophrenia. Whereas IL-2 specifically marks severity of the motivation and pleasure domain of negative symptoms, IL-1β is not specific to this dimension as it also predicts severity of general and global symptomatology.
Authors: Clara Martínez-Cao; Lorena de la Fuente-Tomás; Ainoa García-Fernández; Leticia González-Blanco; Pilar A Sáiz; María Paz Garcia-Portilla; Julio Bobes Journal: Transl Psychiatry Date: 2022-05-11 Impact factor: 7.989